🌊 $CNTB SEABREEZE SHOCKER 🧵 📊 Phase 2 topline (preliminary, company-reported): • Rademikibart in acute COPD exacerbations • Moderate-to-severe exacerbations:

🌊 $CNTB SEABREEZE SHOCKER 🧵 📊 Phase 2 topline (preliminary, company-reported): • Rademikibart in acute COPD exacerbations • Moderate-to-severe exacerbations: -85% vs placebo 🔥 • Return ER visits: ELIMINATED — zero • Lung function: "clinically meaningful" gain (UAB's Bhatt) 📈 THE TAPE: • Close: …